Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review

  title={Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review},
  author={Igho J. Onakpoya and Carl J. Heneghan and Jeffrey K. Aronson},
  journal={Expert Opinion on Drug Safety},
  pages={63 - 72}
ABSTRACT Introduction: Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attributed to their use have not been systematically assessed. Areas covered: We conducted searches in PubMed; Embase; Google Scholar;; WHO databases of withdrawn products; websites of the European Medicines… 
7 Citations
Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
Non-interventional studies had an important role particularly for the characterisation and quantification of adverse events, the evaluation of product usage and for evaluating the effectiveness of regulatory action to minimise risk.
Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
The need for development of novel cardiac safety testing platform involving combined experimental models of cardiac diseases in the presence and absence of major cardiovascular comorbidities and/or cotreatments is emphasized.
Perceptions of French general practitioners and patients regarding dextropropoxyphene withdrawal: a qualitative study
Apart from physicians who were previously informed of its poor risk-benefit ratio, DXP withdrawal was not a good experience for patients and GPs, but the experience was positive for the GPs who had been alerted to the poor DXP risk- benefit ratio well before its withdrawal.
An historical overview over Pharmacovigilance
This commentary reports the milestones of pharmacovigilance up to the present day, to understand all the steps that have characterized the historical evolution; from the first reports, which were essentially letters or warnings sent by clinicians to publishers of important and famous scientific journals, up to today’s modern and ultra-structured electronic registries.
The application of omics-based human liver platforms for investigating the mechanism of drug-induced hepatotoxicity in vitro
The use of more elaborated human liver models, in harmony with causality-inferring bioinformatic approaches will pave the way for establishing a powerful methodology to systematically assess DILI mechanisms across a wide range of conditions.
Novel Electrotopological Atomic Descriptors for the Prediction of Xenobiotic Cytochrome P450 Reactions
Novel atomic descriptors to predict the sites of metabolism (SoM) in CYP substrates using Gasteiger charge are developed and obtained a gradient boosting decision tree‐based SoM classification model that performed well in terms of the Matthews correlation coefficient.


Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
There are discrepancies in the patterns of withdrawal of medicinal products from the market when adverse reactions are suspected, and withdrawals are inconsistent across countries.
Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
The time it takes for drugs to be withdrawn worldwide after reports of adverse drug reactions has shortened over time, however, there are inconsistencies in current withdrawal procedures when adverseDrug reactions are suspected.
Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis
These results suggest that some deaths associated with medicinal products withdrawn after marketing in association with deaths could have been avoided and manufacturers and regulatory authorities should expedite investigations when deaths are reported as suspected adverse drug reactions and consider early suspensions.
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience
A systematic review of clinical trials data for three different nonsteroidal anti‐inflammatory drugs (NSAIDs) performed in an effort to identify possible early signals that could have predicted post‐marketing serious hepatoxicity.
The Development of New Analgesics Over the Past 50 Years: A Lack of Real Breakthrough Drugs
  • I. Kissin
  • Medicine
    Anesthesia and analgesia
  • 2010
The present assessment reveals the lack of real breakthroughs in analgesic drug development despite intense research efforts, and possible factors contributing to the apparent drought of novel analgesics are discussed.
Pain management with NSAIDs requires some dexterity in particular when certain categories of patients are to be treated, and there is need for continue medical education to ensure rational use of these drugs.
Case reports of suspected adverse drug reactions—systematic literature survey of follow-up
Abstract Objective To determine whether anecdotal reports of suspected adverse drug reactions are valuable early warning signals. Design Systematic literature survey Data sources We evaluated all
Recent advances in the pharmacological management of acute and chronic pain.
Recent advances in the pharmacological management of pain are not so much the result of new 'miracle' drugs, but new preparations and new ways to use old drugs in a variety of settings, often as components of a multimodal approach to pain relief.
Opioids and the treatment of chronic pain: controversies, current status, and future directions.
A narrative review briefly describes the neurobiology of opioids and focuses on the complex issues at this interface between analgesia and abuse, including terminology, clinical challenges, and the potential for new agents, such as buprenorphine, to influence practice.
Three newly approved analgesics: an update.
Lower doses from different drug classes may be employed to reduce the incidence of adverse effects, while producing synergistic analgesia as part of a multimodal analgesic approach to acute pain.